Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status

Frédérique Penault-Llorca; Renata A. Coudry; Wedad M. Hanna; Robert Y. Osamura; Josef Rüschoff; Giuseppe Viale

doi:10.1016/j.breast.2012.12.004

Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status

Frédérique Penault-Llorca, Renata A. Coudry, Wedad M. Hanna, Robert Y. Osamura, Josef Rüschoff, Giuseppe Viale

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

The human epidermal growth factor receptor 2 (HER2) and hormone receptor status of recurrent breast cancer may change between the tumor and metastases from negative to positive and vice versa, potentially affecting the treatment regimen. Retesting of metastases may therefore be crucial to allow appropriate selection of patients for whom targeted therapy is indicated; however, retesting is not routinely performed. This article recommends that metastases be retested for HER2 and hormone receptor status and provides practical guidance on when and how to retest, as agreed by a panel of expert pathologists with extensive experience of HER2 and hormone receptor testing.

Original language	English
Pages (from-to)	200-202
Number of pages	3
Journal	Breast
Volume	22
Issue number	2
DOIs	https://doi.org/10.1016/j.breast.2012.12.004
Publication status	Published - Apr 2013

Keywords

Breast cancer
Estrogen receptors
HER2
Metastasis
Progesterone receptors
Re-biopsy

ASJC Scopus subject areas

Surgery

Access to Document

10.1016/j.breast.2012.12.004

Fingerprint Dive into the research topics of 'Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status'. Together they form a unique fingerprint.

Cite this

@article{31374d2097dc4bb0be38e8430dc5a090,

title = "Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status",

abstract = "The human epidermal growth factor receptor 2 (HER2) and hormone receptor status of recurrent breast cancer may change between the tumor and metastases from negative to positive and vice versa, potentially affecting the treatment regimen. Retesting of metastases may therefore be crucial to allow appropriate selection of patients for whom targeted therapy is indicated; however, retesting is not routinely performed. This article recommends that metastases be retested for HER2 and hormone receptor status and provides practical guidance on when and how to retest, as agreed by a panel of expert pathologists with extensive experience of HER2 and hormone receptor testing.",

keywords = "Breast cancer, Estrogen receptors, HER2, Metastasis, Progesterone receptors, Re-biopsy",

author = "Fr{\'e}d{\'e}rique Penault-Llorca and Coudry, {Renata A.} and Hanna, {Wedad M.} and Osamura, {Robert Y.} and Josef R{\"u}schoff and Giuseppe Viale",

year = "2013",

month = apr,

doi = "10.1016/j.breast.2012.12.004",

language = "English",

volume = "22",

pages = "200--202",

journal = "Breast",

issn = "0960-9776",

publisher = "Churchill Livingstone",

number = "2",

}

TY - JOUR

T1 - Experts' opinion

T2 - Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status

AU - Penault-Llorca, Frédérique

AU - Coudry, Renata A.

AU - Hanna, Wedad M.

AU - Osamura, Robert Y.

AU - Rüschoff, Josef

AU - Viale, Giuseppe

PY - 2013/4

Y1 - 2013/4

N2 - The human epidermal growth factor receptor 2 (HER2) and hormone receptor status of recurrent breast cancer may change between the tumor and metastases from negative to positive and vice versa, potentially affecting the treatment regimen. Retesting of metastases may therefore be crucial to allow appropriate selection of patients for whom targeted therapy is indicated; however, retesting is not routinely performed. This article recommends that metastases be retested for HER2 and hormone receptor status and provides practical guidance on when and how to retest, as agreed by a panel of expert pathologists with extensive experience of HER2 and hormone receptor testing.

AB - The human epidermal growth factor receptor 2 (HER2) and hormone receptor status of recurrent breast cancer may change between the tumor and metastases from negative to positive and vice versa, potentially affecting the treatment regimen. Retesting of metastases may therefore be crucial to allow appropriate selection of patients for whom targeted therapy is indicated; however, retesting is not routinely performed. This article recommends that metastases be retested for HER2 and hormone receptor status and provides practical guidance on when and how to retest, as agreed by a panel of expert pathologists with extensive experience of HER2 and hormone receptor testing.

KW - Breast cancer

KW - Estrogen receptors

KW - HER2

KW - Metastasis

KW - Progesterone receptors

KW - Re-biopsy

UR - http://www.scopus.com/inward/record.url?scp=84875545819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875545819&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2012.12.004

DO - 10.1016/j.breast.2012.12.004

M3 - Article

C2 - 23352656

AN - SCOPUS:84875545819

VL - 22

SP - 200

EP - 202

JO - Breast

JF - Breast

SN - 0960-9776

IS - 2

ER -

Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this